Treatment for wet age related Macular Degeneration

New treatments for wet AMD stabilise and even restore lost vision.
The last few years have brought significant progress in the treatment of AMD. With the advent of recent new pharmacological treatments such as bevacizumab (Avastin) and ranibizumab (Lucentis) which inhibit the growth of abnormal vessels. These advances have become much more significant.

These drugs (which are administered through injections inside the eye) have been shown very efficient to inhibit the growth of vessels responsible for the disease and thus stop the evolution of disease and the visual loss that ensues. These new medications even allow a significant number of patients to have improved vision in the presence of AMD.

The main challenge associated with these new treatments is the need to provide the treatment as early as possible in the presence of an active disease in order to preserve the best possible vision, thus the importance of detecting any complication or new activity of the disease as soon as it appears.

Treatment for dry Macular Degeneration

Although there is currently no treatment for dry age related macular degeneration, many drugs are currently under investigation for this disease and researchers are hoping for good results in a near future.
Hopefully soon it will be possible to implement beneficial preventive strategies, long before visual loss from AMD develops and even before the disease process involved in AMD becomes established.